All articles tagged: Opioid use, unspecified, uncomplicated (F11.90)

Many people do not know that a primary care provider (PCP) can provide medication for opioid use disorder (MOUD), according to a research letter published online June 28 in JAMA Network Open.Brandon del Pozo, Ph.D., from the Brown University School of Public Health in Providence, Rhode Island, and colleagues surveyed 1,234 individu

For individuals with opioid use disorder receiving methadone maintenance treatment (MMT), eight weeks of acupuncture is superior to sham acupuncture for reducing methadone dose and opioid craving, according to a study published online July 9 in the Annals of Internal Medicine.Liming Lu, M.D., from the Guangzhou University of Chinese Medi

A considerable proportion of adults reporting illegally manufactured fentanyl (IMF) or heroin use also use xylazine, according to research published in the July 4 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.Xinyi Jiang, Ph.D., from the CDC in Atlanta, and colleagues identified a conv

Psychostimulants may help opioid use disorder (OUD) outcomes in pregnant women, according to a study published online June 11 in Nature Mental Health.Kevin Y. Xu, M.D., M.P.H., from the Washington University School of Medicine in St. Louis, and colleagues used U.S. multistate administrative data to examine the risks and benef

About one-third of community outpatient mental health treatment facilities (MHTFs) offer medications for opioid use disorder (MOUD), according to a study published online June 18 in JAMA Network Open.Jonathan Cantor, Ph.D., from RAND in Santa Monica, California, and colleagues quantified the availability of MOUD at community outpatien

In the 12 months after a nonfatal overdose, few Medicare beneficiaries receive medications for opioid use disorder (MOUD) or fill a naloxone prescription, according to a study published online June 17 in JAMA Internal Medicine.Christopher M. Jones, Pharm.D., Dr.P.H., from the Substance Abuse and Mental Health Services Administration in

Prenatal opioid exposure (POE) is associated with an increased risk for infection, eczema and dermatitis, and asthma in offspring, but it is not linked to allergies or anaphylaxis, according to a study published online Jan. 17 in JAMA Network Open.Erin Kelty, Ph.D., from the University of Western Australia in Crawley, and colleagues com

Incident use of common behavioral health medications remained relatively stable during the COVID-19 pandemic, with the exception of those for attention-deficit/hyperactivity disorder (ADHD), according to a study published online Jan. 10 in JAMA Psychiatry.Grace Chai, Pharm.D., M.P.H., from the U.S. Food and Drug Administration i

For adolescents, access to U.S. residential addiction treatment centers is limited and costly, according to a study published in the January issue of Health Affairs.Caroline A. King, M.P.H., from Oregon Health & Science University in Portland, and colleagues identified 160 residential addiction treatment facilities that treated adol

Telehealth-delivered mindfulness-oriented recovery enhancement (MORE) is a feasible and effective adjunct to methadone treatment (MT) for individuals with opioid use disorder (OUD) and pain, according to a study published online Dec. 7 in JAMA Psychiatry.Nina A. Cooperman, Psy.D., from Rutgers Robert Wood Johnson Medical School in P

Telehealth-delivered mindfulness-oriented recovery enhancement (MORE) is a feasible and effective adjunct to methadone treatment (MT) for individuals with opioid use disorder (OUD) and pain, according to a study published online Dec. 7 in JAMA Psychiatry.Nina A. Cooperman, Psy.D., from Rutgers Robert Wood Johnson Medical School in P

Before-medically-advised (BMA) discharges increased to one in six patients from 2016 to 2020 for admissions with opioid use disorder (OUD) and an injection-related infection, according to a research letter published in the Dec. 4 issue of the Journal of the American Medical Association.Ashish P. Thakrar, M.D., from the University

Kentucky is seeking federal approval to study ibogaine, a psychedelic drug from West Africa, as a potential treatment for opioid addiction. Ibogaine has shown promise in reducing withdrawal symptoms and cravings, presenting an alternative approach to traditional addiction treatments.

The U.S. Food and Drug Administration has approved a first-of-its-kind test -- the AvertD test -- that uses DNA swabbed from a patient's cheek to determine if they have a combination of genetic variants associated with an elevated risk for opioid addiction.The 15 genetic variants detected by the test are involved in the brain reward pathways t

Kentucky is launching a pilot program to study the use of the psychedelic drug ibogaine as a potential treatment for opioid addiction, despite its federal illegality. Derived from a West African shrub, ibogaine shows promise in combating the opioid crisis, and this initiative seeks to assess its effectiveness and safety.

Opioid prescribing by physicians and other health professionals has decreased for the 13th consecutive year, down nearly 50 percent since 2012, while overdoses and deaths related to illicitly manufactured fentanyl, xylazine, and other synthetic substances continue to increase, according to the Overdose Epidemic Report 2023, released by

In recent years, the healthcare industry has witnessed a transformative shift towards telemedicine. This innovative approach to healthcare delivery has proven to be not only convenient but also highly effective, especially in addressing complex issues like opioid use disorder. In this article, we will explore how telemedicine has revolutionized the initiation of buprenorphine treatment for individ